TY - JOUR T1 - Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure JF - Gut JO - Gut SP - 1787 LP - 1795 DO - 10.1136/gutjnl-2018-318172 VL - 69 IS - 10 AU - Loris Pironi AU - Ezra Steiger AU - Francisca Joly AU - Geert J A Wanten AU - Cecile Chambrier AU - Umberto Aimasso AU - Anna Simona Sasdelli AU - Kinga Szczepanek AU - Amelia Jukes AU - Miriam Theilla AU - Marek Kunecki AU - Joanne Daniels AU - Mireille J Serlie AU - Sheldon C Cooper AU - Florian Poullenot AU - Henrik Højgaard Rasmussen AU - Charlene W Compher AU - Adriana Crivelli AU - Sarah-Jane Hughes AU - Lidia Santarpia AU - Francesco William Guglielmi AU - Nada Rotovnik Kozjek AU - Lars Ellegard AU - Stéphane M Schneider AU - Przemysław Matras AU - Alastair Forbes AU - Nicola Wyer AU - Anna Zmarzly AU - Marina Taus AU - Margie O'Callaghan AU - Emma Osland AU - Ronan Thibault AU - Cristina Cuerda AU - Lynn Jones AU - Brooke Chapman AU - Peter Sahin AU - Núria M Virgili AU - Andre Dong Won Lee AU - Paolo Orlandoni AU - Konrad Matysiak AU - Simona Di Caro AU - Maryana Doitchinova-Simeonova AU - Luisa Masconale AU - Corrado Spaggiari AU - Carmen Garde AU - Aurora E Serralde-Zúñiga AU - Gabriel Olveira AU - Zeljko Krznaric AU - Estrella Petrina Jáuregui AU - Ana Zugasti Murillo AU - José P Suárez-Llanos AU - Elena Nardi AU - André Van Gossum AU - Simon Lal Y1 - 2020/10/01 UR - http://gut.bmj.com/content/69/10/1787.abstract N2 - Background and aim No marker to categorise the severity of chronic intestinal failure (CIF) has been developed. A 1-year international survey was carried out to investigate whether the European Society for Clinical Nutrition and Metabolism clinical classification of CIF, based on the type and volume of the intravenous supplementation (IVS), could be an indicator of CIF severity.Methods At baseline, participating home parenteral nutrition (HPN) centres enrolled all adults with ongoing CIF due to non-malignant disease; demographic data, body mass index, CIF mechanism, underlying disease, HPN duration and IVS category were recorded for each patient. The type of IVS was classified as fluid and electrolyte alone (FE) or parenteral nutrition admixture (PN). The mean daily IVS volume, calculated on a weekly basis, was categorised as <1, 1–2, 2–3 and >3 L/day. The severity of CIF was determined by patient outcome (still on HPN, weaned from HPN, deceased) and the occurrence of major HPN/CIF-related complications: intestinal failure-associated liver disease (IFALD), catheter-related venous thrombosis and catheter-related bloodstream infection (CRBSI).Results Fifty-one HPN centres included 2194 patients. The analysis showed that both IVS type and volume were independently associated with the odds of weaning from HPN (significantly higher for PN <1 L/day than for FE and all PN >1 L/day), patients’ death (lower for FE, p=0.079), presence of IFALD cholestasis/liver failure and occurrence of CRBSI (significantly higher for PN 2–3 and PN >3 L/day).Conclusions The type and volume of IVS required by patients with CIF could be indicators to categorise the severity of CIF in both clinical practice and research protocols. ER -